Skip to main content

Table 1 Baseline characteristics of HIV/HBV co-infected patients and by antiretroviral treatment Status

From: Proportion and factors associated with Hepatitis B viremia in antiretroviral treatment naïve and experienced HIV co-infected Ghanaian patients

  

Treatment status

  

Characteristic

All patients (N = 235)

Experienced (N = 152)

Naïve (N = 83)

P value T test

P value Wilcoxon rank sum test

Mean (SD) age (years)

41.0 (10.0)

42.6 (9.5)

37.9 (10.2)

0.0006

<0.0001

Mean (SD) weight (kg)

63.1 (13.4)

64.9 (13.1)

59.6 (13.2)

0.0038

0.0082

Mean (SD) BMI (kg/m2)

23.4 (4.7)

24.2 (4.7)

21.8 (4.5)

0.0001

0.0002

Mean (SD) CD4 count (cells/uL)

460.7 (322)

513 (304)

363 (334)

0.0006

<0.0001

 

n (%)

n (%)

n (%)

P value Chi square

P value Fisher

Sex

   

0.597

0.677

 Female

139 (59.1)

88 (57.9)

51 (61.5)

  

 Male

96 (40.9)

64 (42.1)

32 (38.6)

  

Ethnicity

   

0.744

0.762

 Akan

109 (46.8)

72 (47.4)

37 (45.7)

  

 Ewe

44 (18.9)

29 (19.1)

15 (18.5)

  

 Ga

28 (12.0)

20 (13.1)

8 (9.9)

  

 Other

52 (22.3)

31 (20.4)

21 (25.9)

  

WHO HIV stage

   

0.630

0.619

 1

55 (23.7)

38 (25.3)

17 (20.7)

  

 2

58 (25.0)

36 (24.0)

22 (26.8)

  

 3

92 (39.7)

61 (40.7)

31 (37.8)

  

 4

27 (11.6)

15 (10.0)

12 (14.6)

  

HBeAg positive

47 (20.0)

28 (18.4)

19 (22.9)

0.413

0.495

HBeAb positive

188 (80.0)

122 (80.3)

66 (79.5)

0.891

1.000

HBeAg/eAb combination

   

0.622

0.604

HBeAg positive/Ab negative

41 (17.5)

25 (16.5)

16 (19.3)

  

HBeAg negative/Ab positive

182 (77.5)

119 (78.3)

63 (75.9)

  

HBeAg negative/Ab negative

6 (2.6)

5 (3.3)

1 (1.2)

  

HBcIgM positive

5 (2.1)

4 (2.6)

1 (1.2)

0.469

0.659

  

Treatment status

  

Characteristic

All patients

Experienced

Naïve

P value Chi square

P value Fisher

N = 235 (%)

(N = 152)

(N = 83)

n (%)

n (%)

Alanine aminotransferase

   

0.0012

0.0015

 Normal (5-40 U/L)

169 (71.9)

120 (79.0)

49 (59.0)

  

 Elevated > ULN

66 (28.1)

32 (21.1)

34 (41.0)

  

Aspartate aminotransferase

   

0.0005

0.0008

 Normal (5-50 U/L)

178 (75.7)

126 (82.9)

52 (62.7)

  

 Elevated > ULN

57 (24.3)

26 (17.1)

30 (36.1)

  

Albumin

   

<0.0001

<0.0001

 Normal (36-50)

153 (65.1)

117 (77.0)

36 (43.4)

  

 Low < LLN

82 (34.9)

35 (23.0)

47 (56.6)

  

HBV DNA (IU mL-1)

   

<0.0001

<0.0001

  < 20

97 (41.3)

88 (57.9)

9 (10.8)

  

 20 – 2000

58 (24.7)

31 (20.4)

27 (32.5)

  

 2001 - 20, 000

14 (6.0)

4 (2.6)

10 (12.1)

  

  > 20, 000

66 (28.1)

29 (19.1)

37 (44.6)

  

Initial ART contain

     

 3TC

100 (42.6)

100 (65.8)

--

  

 3TC + TDF

52 (22.1)

52 (34.2)

--

  

Duration on ART

  

--

  

<1 year

4 (1.7)

4 (2.6)

   

 1 – 2 years

38 (16.2)

38 (25.0)

--

  

 2 – 3 years

21 (8.9)

21 (13.8)

--

  

  > 3 years

89 (37.9)

89 (58.6)

--

  

Ever forgotten meds?

 

36 (23.7)

--

  

Do you take meds on time?

 

16 (10.5)

--

  

Stop taking meds due to illness?

 

12 (7.9)

--

  

Forgotten meds last weekend?

 

14 (9.2)

--

  

Number of times not taken meds last week?

     

 0

 

57 (37.5)

   

 1 to 2

 

10 (6.6)

   

 3 – 5

 

6 (3.9)

   

 more than 5

 

3 (2.0)

   
  1. BMI body mass index
  2. HBeAg/Ab Hepatitis B e Antigen/Antibody
  3. HBcIgM Hepatitis B core IgM
  4. 3TC lamivudine
  5. TDF tenofovir
  6. ULN upper limit of normal
  7. LLN lower limit of normal
  8. ART anti-retroviral therapy